Sture Falkmer
- Oncology top 1%
- Pancreatic and Hepatic Oncology Research 21
- Lung Cancer Research Studies 18
-
- Neuropeptides and Animal Physiology 16
- Geriatrics and Gerontology top 2%
- Neurology top 2%
- Neuroblastoma Research and Treatments 20
-
- Pancreatic function and diabetes 40
-
- Neuroendocrine Tumor Research Advances 35
-
- Cancer Genomics and Diagnostics 23
-
- Diabetes and associated disorders 15
Sture Falkmer
237 papers receiving 6.2k citations
Peers
Comparison fields: 5 of 146
- Oncology 1.7k
- Endocrinology, Diabetes and Metabolism 978
- Cellular and Molecular Neuroscience 890
- Geriatrics and Gerontology 169
- Neurology 608
Countries citing papers authored by Sture Falkmer
This map shows the geographic impact of Sture Falkmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sture Falkmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sture Falkmer more than expected).
Fields of papers citing papers by Sture Falkmer
This network shows the impact of papers produced by Sture Falkmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sture Falkmer. The network helps show where Sture Falkmer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sture Falkmer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2023 | 4 | |
| 3 | 2023 | 0 | |
| 4 | 2023 | 2 | |
| 5 | 2022 | 1 | |
| 6 | 2022 | 2 | |
| 7 | 2022 | 5 | |
| 8 | 2021 | 3 | |
| 9 | 2021 | 12 | |
| 10 | 2020 | 15 | |
| 11 | 2018 | 23 | |
| 12 | 2016 | 37 | |
| 13 | Perifert inlagd central venkateter ännu inte utvärderad för kliniskt bruk: Mer vetenskapligt stöd krävs, visar litteraturstudie | 2008 | 0 |
| 14 | 1999 | 22 | |
| 15 | 1993 | 18 | |
| 16 | Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer. | 1992 | 18 |
| 17 | 1992 | 19 | |
| 18 | 1991 | 38 | |
| 19 | Comparative effects in vitro of Myxine, Squalus, Avian and mammalian insulins on DNA-synthesis in 3T3 mouse fibroblasts | 1988 | 1 |
| 20 | Onto- and phylogenetical aspects on insulin-producing islet-cell tumors. | 1976 | 3 |
About Sture Falkmer
Sture Falkmer is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Cancer Research, having authored 244 papers that have together received 6.4k indexed citations. Recurring topics across this work include Pancreatic function and diabetes (40 papers), Neuroendocrine Tumor Research Advances (35 papers), Cancer Genomics and Diagnostics (23 papers), Pancreatic and Hepatic Oncology Research (21 papers), Neuroblastoma Research and Treatments (20 papers), Lung Cancer Research Studies (18 papers), Neuropeptides and Animal Physiology (16 papers) and Diabetes and associated disorders (15 papers). The work is most often cited by research in Oncology (1.7k citations), Endocrinology, Diabetes and Metabolism (978 citations) and Cellular and Molecular Neuroscience (890 citations). Sture Falkmer has collaborated with scholars based in Sweden, Denmark and Norway. Frequent co-authors include Lars Grimelius, J. Alumets, Per‐Anders Abrahamsson, M. Reinecke, Lene Thoresen, K Fält, F. Sundler, Lars B. Wadström, Gert Auer and Donald F. Steiner. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.